Studying a gene's role in liver cancer spread
Part of Cancer, Digestive system clinical trials.
This trial looks at a specific gene (LINC01134) to see if it helps liver cancer spread in people with hepatitis C. The goal is to better understand why some cancers spread, which could lead to new treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a hepatitis C infection (positive antibodies and virus for more than 6 months).
- You have liver cirrhosis, which is scarred liver tissue.
- You have been diagnosed with liver cancer (HCC) based on imaging or high AFP levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for people with or without liver cancer to test a new way to find liver cancer early using blood or tissue samples. It aims to help catch the disease sooner.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
This study looks at a 29-gene test to see if it can predict how well liver cancer responds to targeted therapy plus immunotherapy. If you have liver cancer and are getting this type of treatment, your stored tumor sample might help researchers learn more.
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.